Log In Sign up
The largest database of trusted experimental protocols

Motesanib

Manufactured by LC Laboratories
Visit Supplier
Sourced in United States

Motesanib is a small-molecule kinase inhibitor developed by LC Laboratories. It targets multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor (c-Kit).

Automatically generated - may contain errors

Lab products found in correlation

Bafetinib, by Selleck Chemicals (2 mentions) Tivozanib, by Selleck Chemicals (2 mentions) Az628, by Selleck Chemicals (2 mentions) Doramapimod, by Selleck Chemicals (2 mentions) Bms 777607, by Selleck Chemicals (2 mentions) Braf inhibitor 1, by ChemScene (2 mentions) Rebastinib, by ChemScene (2 mentions) Foretinib, by LC Laboratories (2 mentions) Regorafenib, by Selleck Chemicals (1 mentions) Suramin, by Merck Group (1 mentions) Flavopiridol, by Merck Group (1 mentions) Cabozantinib, by Selleck Chemicals (1 mentions) Sorafenib, by Merck Group (1 mentions) Thalidomide, by Merck Group (1 mentions) Tnp 470, by Merck Group (1 mentions) Axitinib, by Selleck Chemicals (1 mentions) Su5416, by Merck Group (1 mentions) Paclitaxel, by Merck Group (1 mentions) Pazopanib, by LC Laboratories (1 mentions) Vatalanib, by LC Laboratories (1 mentions)

3 protocols using motesanib

1

Procuring Validated Type II Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine structurally validated type II
inhibitors, which are commercially available, were procured form chemical
vendors. Foretinib and motesanib free bases were obtained from LC
Laboratories. Doramapimod, bafetinib, tivozanib, BMS-777607, and AZ-628
were obtained from Selleck Chem. BRAF inhibitor 1 and rebastinib were
obtained from Chemscene. The compounds obtained had an average purity
of >96%.
Vijayan R.S., He P., Modi V., Duong-Ly K.C., Ma H., Peterson J.R., Dunbrack RL J.r, & Levy R.M. (2014). Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of Medicinal Chemistry, 58(1), 466-479.
+ Open protocol
+ Expand
2

Procurement of Validated Type II Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nine structurally validated type II inhibitors, which are commercially available were procured form chemical vendors. Foretinib and Motesanib free bases were obtained from LC Laboratories. Doramapimod, Bafetinib, Tivozanib, BMS-777607 and AZ-628 were obtained from Selleck Chem. BRAF inhibitor 1 and Rebastinib were obtained from Chemscene. The compounds obtained had an average purity > 96%.
Vijayan R.S., He P., Modi V., Duong-Ly K.C., Ma H., Peterson J.R., Dunbrack RL J.r, & Levy R.M. (2014). Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors. Journal of Medicinal Chemistry, 58(1), 466-479.
+ Open protocol
+ Expand
3

Evaluating Anti-Angiogenic Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
The anti-angiogenic compounds SU5416, combretastatin, thalidomide, TNP-470, flavopiridol, suramin, paclitaxel, and sorafenib were purchased from Sigma-Aldrich Co. (St Louis, MO, USA); vatalanib, motesanib, pazopanib, tivozanib, and vandetanib were purchased from LC Laboratories (Woburn, MA, USA). Axitinib, cabozantinib, and regorafenib were purchased from Selleck Chemicals (Houston, TX, USA). All other chemicals used in this study were obtained from Sigma-Aldrich Co., unless mentioned otherwise.
Chimote G., Sreenivasan J., Pawar N., Subramanian J., Sivaramakrishnan H, & Sharma S. (2014). Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery. Drug Design, Development and Therapy, 8, 1107-1123.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!